Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Sarah Kehr; Philipp Berg; Susanne Müller; Sarah A Fiedler; Britta Meyer; Gabriele Ruppert-Seipp; Cornelia Witzenhausen; Marc E Wolf; Hans H Henkes; Doris Oberle; Brigitte Keller-Stanislawski; Markus B Funk

doi:10.1038/s41541-022-00491-z

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

NPJ Vaccines. 2022 Jul 5;7(1):76. doi: 10.1038/s41541-022-00491-z.

Affiliations

¹ Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
² Department of Neurology, Klinikum Stuttgart, Stuttgart, Germany.
³ Department of Neuroradiology Klinikum Stuttgart, Stuttgart, Germany.
⁴ Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany. markus.funk@pei.de.

Abstract

We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3-6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).